Future of Human Papillomavirus (HPV) Vaccines Market Growth (2025-2033) | Global Cervical Cancer Prevention Dosage, Supply, Production

human papillomavirus (HPV) vaccine market was valued at USD 3,043.19 million in 2024 and is projected to reach USD 12,361.15 million by 2033, expanding at a CAGR of 16.9% during the forecast period 2025-2033.

✅ North America human papillomavirus (HPV) vaccine market was valued at USD 1,143.64 million in 2024 and is expected to reach USD 4,819.32 million by 2033, expanding at a CAGR of 15.3% over the forecast period 2025-2033

✅ Asia-Pacific human papillomavirus (HPV) vaccine market was valued at USD 605.23 million in 2024 and is projected to reach USD 3,292.92 million by 2033, registering a CAGR of 18.3% during the forecast period 2025-2033.

Get a Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/human-papillomavirus-vaccines-market?kb

シルガード®9 (Silgard®9):

✅ Target population: Approved for males and females aged 16 years and older.

✅ Vaccine type: 9-valent HPV vaccine offering broader strain coverage.

✅ HPV strain coverage: Protects against 9 HPV types linked to cancer and genital warts.

✅ Disease prevention: Helps prevent cervical cancer and multiple HPV-related precancerous lesions.

✅ Immunization schedule: Administered as a 3-dose regimen at 0, 2, and 6 months.

Gardasil® received approval in Japan in 2011 and offers protection against nine high-risk HPV types, accounting for nearly 90% of cervical cancer-causing strains.

• Vaccine coverage: Sylgard®9 protects against 9 HPV strains, while Gardasil® covers 4 strains.

• Target group: Both vaccines are approved for individuals aged 16 years and older.

• Disease prevention: Both prevent cervical cancer and related precancerous lesions; Gardasil® additionally covers anal cancer.

• Dosage schedule: Both require 3 doses administered at 0, 2, and 6 months.

• Safety profile: Both vaccines may cause mild injection-site reactions and short-term fever or headache.

• Pricing: Sylgard®9 costs ¥38,500 per dose, while Gardasil® is priced at ¥22,000 per dose (tax included).

Latest M & A

• Merck & Co continues to face strategic challenges with its HPV vaccine Gardasil due to paused China shipments and policy changes impacting sales momentum.

• Sunflower Therapeutics and SK bioscience hit a milestone in their HPV vaccine collaboration, advancing commercialization activities tied to a next-gen 10-valent HPV vaccine.

• Recbio & Biological E partnership for technology transfer/licensing on Recbio's 9-valent HPV vaccine strengthens global manufacturing reach - a market consolidation move (India + UNICEF/PAHO tender participation) from mid-2025 with ongoing impact.

Key Players:

Merck & Co., Inc., GSK plc, Wantai BioPharm., Walvax Biotechnology Co., Ltd., Serum Institute of India Pvt. Ltd., and Jiangsu Recbio Technology Co., Ltd

(Emerging Players)

Emerging companies in the human papillomavirus (HPV) vaccine market include DCVMN International, Shanghai Zerun Biotech Co., Ltd., Shanghai Bovax Biotechnology Co., Ltd., Jiangsu Recbio Technology Co., Ltd., Toragen, BlueSky Immunotherapies, Antiva Biosciences, Precigen, INOVIO Pharmaceuticals, and BioNTech SE

Key Development:

United States

🔹 Nov 2025 - CDC's updated childhood immunization schedule now recommends a single HPV vaccine dose (vs prior 2-3), impacting Gardasil uptake and market dynamics.

🔹 Dec 2025 - Merck's Gardasil sales drop and company adjusts outlook after policy and demand shifts.

🔹 Jan 2026 - Ongoing data indicate HPV vaccination significantly reduces cervical precancerous lesions in young US women (CDC evidence).

Japan

🔹 Nov 2025 - Japan approves the 9-valent HPV vaccine (Silgard®9) for male vaccination, expanding gender-inclusive prevention options outside routine schedule.

🔹 Dec 2025 - National vaccination efforts continue, with catch-up programs extending public-funded doses through early 2026.

🔹 Jan 2026 - HPV vaccine coverage and public awareness efforts continue amid evolving policy discussions about routine male inclusion.

Europe

🔹 Nov 2025 - The HPV Prevention Policy Atlas is launched in Poland, providing detailed insights on vaccination and screening efforts across EU states.

🔹 Dec 2025 - Gavi's tracking shows HPV vaccination programs have reached an estimated 86 million girls globally by end-2025, underscoring broad European engagement in elimination goals.

🔹 Jan 2026 - European Immunisation Week campaigns promote strengthened HPV vaccination protection alongside other routine vaccines

Growth Forecast Projected:

The Global Human Papillomavirus (HPV) Vaccines Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Human Papillomavirus (HPV) Vaccines Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=human-papillomavirus-vaccines-market?kb

Key Segments:

Cervical cancer segment was valued at USD 1,668.33 million in 2024 and is projected to reach USD 6,469.87 million by 2033, registering a CAGR of 14.4% during the forecast period 2025-2033

By Type

• Nonavalent vaccines dominate the market with the largest share, driven by broader protection against 9 HPV strains and strong uptake in national immunization programs.

• Quadrivalent vaccines hold a significant share, supported by long-term use and protection against HPV 6, 11, 16, and 18.

• Bivalent vaccines account for a smaller but steady share, mainly focused on cervical cancer prevention in cost-sensitive markets.

By Gender

• Female population represents the majority market share, driven by cervical cancer prevention initiatives and higher vaccination awareness.

• Male vaccination is a fast-growing segment, supported by rising awareness of HPV-related cancers and gender-neutral vaccination policies.

By Age Group

• Children & adolescents account for the largest share, as vaccination is most effective before HPV exposure and widely included in school-based programs.

• Adults hold a notable share, driven by catch-up vaccination and expanding age recommendations.

• Geriatrics represent a limited share, due to lower clinical emphasis and reduced vaccine efficacy at older ages.

By End Users

• Hospitals dominate with the highest share, supported by large immunization volumes and government-backed vaccination drives.

• Clinics capture a substantial share, driven by accessibility and routine outpatient vaccination services.

• Others (public health centers, NGOs) contribute a smaller share, mainly through community-based programs.

Regional Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/human-papillomavirus-vaccines-market?kb

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?kb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Contact Us For Custom Research: https://www.datamintelligence.com/custom-research?kb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.